Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3529]

ASCO 2015: MEDI4736 tremelimumab combo shows activity in NSCLC

ASCO 2015: MEDI4736 tremelimumab combo shows activity in NSCLC

ASCO 2015: Phase III study finds initial nivolumab-based treatment halts melanoma progression

ASCO 2015: Phase III study finds initial nivolumab-based treatment halts melanoma progression

ASCO 2015: First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

ASCO 2015: First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

ASCO 2015: Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

ASCO 2015: Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

ASCO 2015: New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

ASCO 2015: New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

ASCO 2015: Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

ASCO 2015: Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

ASCO 2015: Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial

ASCO 2015: Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial

ASCO 2015: Pembrolizumab shows promising activity against head and neck cancer

ASCO 2015: Pembrolizumab shows promising activity against head and neck cancer

ASCO 2015: Nivolumab extends survival for patients with the most common lung cancer

ASCO 2015: Nivolumab extends survival for patients with the most common lung cancer

ASCO 2015: Genomic marker predicts anti-PD-1 response in several cancers

ASCO 2015: Genomic marker predicts anti-PD-1 response in several cancers

More from ecancer